Targeting Sex Steroid Biosynthesis for Breast and Prostate Cancer Therapy

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2023 Sep 8

PMID 37684402

Authors

Matti Poutanen

Malin Hagberg Thulin

Pirkko Harkonen

Affiliations

Soon will be listed here.

Citing Articles

Novel biomarkers and drug correlations of non-canonical WNT signaling in prostate and breast cancer.

Huang Y, Fan M, Liu Y, Jiang X, Du K, Wu A Discov Oncol. 2024; 15(1):511.

PMID: 39347881 PMC: 11442966. DOI: 10.1007/s12672-024-01394-2.

Targeting the cancer cells and cancer-associated fibroblasts with next-generation FGFR inhibitors in prostate cancer co-culture models.

Afshan S, Kim Y, Mattsson J, Akerfelt M, Harkonen P, Baumgartner M Cancer Med. 2024; 13(18):e70240.

PMID: 39300962 PMC: 11413502. DOI: 10.1002/cam4.70240.

Trends in research on nanomedicine in urologic cancer: a bibliometric and visualized analysis.

Lan X, Feng M, Chen L, Zhang L, Han C, Wang Y Discov Oncol. 2024; 15(1):366.

PMID: 39179938 PMC: 11343939. DOI: 10.1007/s12672-024-01249-w.

Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.

Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y Signal Transduct Target Ther. 2024; 9(1):149.

PMID: 38890350 PMC: 11189549. DOI: 10.1038/s41392-024-01848-7.

Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death.

Gao X, Zhao H, Liu J, Wang M, Dai Z, Hao W Adv Sci (Weinh). 2024; 11(30):e2401396.

PMID: 38859590 PMC: 11321675. DOI: 10.1002/advs.202401396.

References

Schrader W, OMalley B . Steroid receptor family: structure and functions. Endocr Rev. 1990; 11(2):201-20. DOI: 10.1210/edrv-11-2-201. View

Simpson E, Misso M, Hewitt K, Hill R, Boon W, Jones M . Estrogen--the good, the bad, and the unexpected. Endocr Rev. 2005; 26(3):322-30. DOI: 10.1210/er.2004-0020. View

Russell N, Grossmann M . MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone. Eur J Endocrinol. 2019; 181(1):R23-R43. DOI: 10.1530/EJE-18-1000. View

Walters K, Simanainen U, Gibson D . Androgen action in female reproductive physiology. Curr Opin Endocrinol Diabetes Obes. 2016; 23(3):291-6. DOI: 10.1097/MED.0000000000000246. View

Elzenaty R, du Toit T, Fluck C . Basics of androgen synthesis and action. Best Pract Res Clin Endocrinol Metab. 2022; 36(4):101665. DOI: 10.1016/j.beem.2022.101665. View

Tsai M, OMalley B . Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994; 63:451-86. DOI: 10.1146/annurev.bi.63.070194.002315. View

Ruff M, Gangloff M, Wurtz J, Moras D . Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Res. 2001; 2(5):353-9. PMC: 138657. DOI: 10.1186/bcr80. View

Shiau A, Barstad D, Loria P, Cheng L, Kushner P, Agard D . The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1999; 95(7):927-37. DOI: 10.1016/s0092-8674(00)81717-1. View

El Kharraz S, Dubois V, van Royen M, Houtsmuller A, Pavlova E, Atanassova N . The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation. EMBO Rep. 2021; 22(12):e52764. PMC: 8647150. DOI: 10.15252/embr.202152764. View

10.

Heemers H, Tindall D . Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007; 28(7):778-808. DOI: 10.1210/er.2007-0019. View

11.

Carroll J, Liu X, Brodsky A, Li W, Meyer C, Szary A . Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005; 122(1):33-43. DOI: 10.1016/j.cell.2005.05.008. View

12.

Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A . Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011; 30(19):3962-76. PMC: 3209787. DOI: 10.1038/emboj.2011.328. View

13.

Le Dily F, Vidal E, Cuartero Y, Quilez J, Nacht A, Vicent G . Hormone-control regions mediate steroid receptor-dependent genome organization. Genome Res. 2018; 29(1):29-39. PMC: 6314164. DOI: 10.1101/gr.243824.118. View

14.

Paakinaho V, Palvimo J . Genome-wide crosstalk between steroid receptors in breast and prostate cancers. Endocr Relat Cancer. 2021; 28(9):R231-R250. PMC: 8345902. DOI: 10.1530/ERC-21-0038. View

15.

Zhao L, Zhou S, Gustafsson J . Nuclear Receptors: Recent Drug Discovery for Cancer Therapies. Endocr Rev. 2019; 40(5):1207-1249. DOI: 10.1210/er.2018-00222. View

16.

Westaby D, Fenor de La Maza M, Paschalis A, Jimenez-Vacas J, Welti J, de Bono J . A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. Annu Rev Pharmacol Toxicol. 2021; 62:131-153. DOI: 10.1146/annurev-pharmtox-052220-015912. View

17.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C . In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995; 9(4):401-6. DOI: 10.1038/ng0495-401. View

18.

Chen C, Welsbie D, Tran C, Baek S, Chen R, Vessella R . Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-9. DOI: 10.1038/nm972. View

19.

Howlader N, Altekruse S, Li C, Chen V, Clarke C, Ries L . US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106(5). PMC: 4580552. DOI: 10.1093/jnci/dju055. View

20.

Anderson W, Chatterjee N, Ershler W, Brawley O . Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002; 76(1):27-36. DOI: 10.1023/a:1020299707510. View